Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review.
Aromatase inhibitor
Cabergoline
Dopamine agonist
Prolactinoma
Testosterone
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
08 Nov 2023
08 Nov 2023
Historique:
received:
21
08
2023
accepted:
19
10
2023
pubmed:
8
11
2023
medline:
8
11
2023
entrez:
8
11
2023
Statut:
aheadofprint
Résumé
To assess the effect of letrozole, an aromatase inhibitor (AI), in patients with resistant prolactinoma that presented an increase in serum prolactin (PRL) levels during testosterone replacement therapy (TRT). A retrospective cohort study in a single tertiary care center. From March 2012 to July 2023, 53 male patients over 18 years with prolactinoma were followed in our Neuroendocrine Unit. Of those, 90.6% presented macroadenomas, 41% of them were resistant to cabergoline and 25% presented persistent hypogonadism to whom TRT was indicated. Among them, five presented a significant increase in PRL levels and AI was initiated. All five patients had resistant prolactinomas. One of them was excluded due to tumor aggressiveness and concomitant use of temozolomide during AI therapy. Four patients were included in the analysis, with a mean age of 28.5 (± 7.5) years, median prolactin of 1060 (600 to 6700) ng/mL and median of the largest tumor diameter of 3.6 (1.5 to 5) cm at the time of prolactinoma diagnosis. On TRT, all presented an increase in serum PRL levels (231 to 396%), with a subsequent decrease (61 to 93%) after adding AI. During AI treatment for a median time of 60.5 (21 to 120) months, tumor shrinkage was observed in two cases (-8 and -3 mm in the maximum diameter) and tumor stability in the other two. No major side effects occurred and AI was well tolerated. AI might be an option for men with resistant prolactinoma who have an increase in PRL levels on TRT. Nevertheless, prospective randomized clinical trials are needed to ensure efficacy and security for this approach.
Identifiants
pubmed: 37938428
doi: 10.1007/s40618-023-02231-z
pii: 10.1007/s40618-023-02231-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Wong A, Eloy JA, Couldwell WT, Liu JK (2015) Update on prolactinomas. Part 1: clinical manifestations and diagnostic challenges. J Clin Neurosci Off J Neurosurg Soc Aust 22(10):1562–1567. https://doi.org/10.1016/j.jocn.2015.03.058
doi: 10.1016/j.jocn.2015.03.058
Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102–2107. https://doi.org/10.1210/jcem.82.7.4088
doi: 10.1210/jcem.82.7.4088
pubmed: 9215279
Tirosh A, Benbassat C, Lifshitz A, Shimon I (2015) Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 18(1):108–115. https://doi.org/10.1007/s11102-014-0563-z
doi: 10.1007/s11102-014-0563-z
pubmed: 24700366
Behan LA, Draman MS, Moran C et al (2011) Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary 14(4):362–366. https://doi.org/10.1007/s11102-009-0168-0
doi: 10.1007/s11102-009-0168-0
pubmed: 19191028
Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109(1):42–50. https://doi.org/10.1159/000495775
doi: 10.1159/000495775
pubmed: 30481756
Passos VQ, Fortes MAHZ, Giannella-Neto D, Bronstein MD (2009) Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89(2):163–170. https://doi.org/10.1159/000156116
doi: 10.1159/000156116
pubmed: 18791324
Souteiro P, Karavitaki N (2020) Dopamine agonist resistant prolactinomas: any alternative medical treatment? Pituitary 23(1):27–37. https://doi.org/10.1007/s11102-019-00987-3
doi: 10.1007/s11102-019-00987-3
pubmed: 31522358
Molitch ME (2014) Management of medically refractory prolactinoma. J Neurooncol 117(3):421–428. https://doi.org/10.1007/s11060-013-1270-8
doi: 10.1007/s11060-013-1270-8
pubmed: 24146188
Sonigo C, Bouilly J, Carré N et al (2012) Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest 122(10):3791–3795. https://doi.org/10.1172/JCI63937
doi: 10.1172/JCI63937
pubmed: 23006326
pmcid: 3461919
Colao A, Vitale G, Cappabianca P et al (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89(4):1704–1711. https://doi.org/10.1210/jc.2003-030979
doi: 10.1210/jc.2003-030979
pubmed: 15070934
Andereggen L, Frey J, Andres RH et al (2017) Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health. World Neurosurg 97:595–602. https://doi.org/10.1016/j.wneu.2016.10.059
doi: 10.1016/j.wneu.2016.10.059
pubmed: 27773859
Mazziotti G, Porcelli T, Mormando M et al (2011) Vertebral fractures in males with prolactinoma. Endocrine 39(3):288–293. https://doi.org/10.1007/s12020-011-9462-5
doi: 10.1007/s12020-011-9462-5
pubmed: 21479837
Gillam MP, Middler S, Freed DJ, Molitch ME (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87(10):4447–4451. https://doi.org/10.1210/jc.2002-020426
doi: 10.1210/jc.2002-020426
pubmed: 12364416
Bonert V (2020) Do nothing but observe microprolactinomas: when and how to replace sex hormones? Pituitary 23(3):307–313. https://doi.org/10.1007/s11102-020-01039-x
doi: 10.1007/s11102-020-01039-x
pubmed: 32274622
Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R (1987) Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64(2):391–394. https://doi.org/10.1210/jcem-64-2-391
doi: 10.1210/jcem-64-2-391
pubmed: 3793856
Sodi R, Fikri R, Diver M, Ranganath L, Vora J (2005) Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature. Ann Clin Biochem 42(Pt 2):153–159. https://doi.org/10.1258/0004563053492784
doi: 10.1258/0004563053492784
pubmed: 15829128
Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. https://doi.org/10.1038/s41574-023-00886-5
doi: 10.1038/s41574-023-00886-5
pubmed: 37670148
Akirov A, Rudman Y (2023) The role of aromatase inhibitors in male prolactinoma. J Clin Med 12(4):1437. https://doi.org/10.3390/jcm12041437
doi: 10.3390/jcm12041437
pubmed: 36835974
pmcid: 9962537
Carretero J, Burks DJ, Vázquez G et al (2002) Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats. Pituitary 5(1):5–10. https://doi.org/10.1023/a:1022176631922
doi: 10.1023/a:1022176631922
pubmed: 12638719
García-Barrado MJ, Blanco EJ, Catalano-Iniesta L et al (2016) Relevance of pituitary aromatase and estradiol on the maintenance of the population of prolactin-positive cells in male mice. Steroids 111:121–126. https://doi.org/10.1016/j.steroids.2016.03.020
doi: 10.1016/j.steroids.2016.03.020
pubmed: 27046736
Akinci H, Kapucu A, Dar KA et al (2013) Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior. Pituitary 16(3):386–392. https://doi.org/10.1007/s11102-012-0436-2
doi: 10.1007/s11102-012-0436-2
pubmed: 22983691
Su YX, Du GL, Shen HL et al (2019) Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women. J Int Med Res 47(7):3115–3126. https://doi.org/10.1177/0300060519848916
doi: 10.1177/0300060519848916
pubmed: 31179796
pmcid: 6683891
García Barrado MJ, Blanco EJ, Carretero Hernández M et al (2014) Local transformations of androgens into estradiol by aromatase P450 is involved in the regulation of prolactin and the proliferation of pituitary prolactin-positive cells. PLoS ONE 9(6):e101403. https://doi.org/10.1371/journal.pone.0101403
doi: 10.1371/journal.pone.0101403
pubmed: 24978194
pmcid: 4076335
Selek A, Halbutoğulları ZSU, Aydemir Çİ et al (2023) Letrozole decreased testosterone-induced cell proliferation and prolactin secretion also increased apoptosis in MMQ and GH3 rat prolactinoma cell lines. Mol Neurobiol 60(5):2442–2454. https://doi.org/10.1007/s12035-023-03220-2
doi: 10.1007/s12035-023-03220-2
pubmed: 36662360
Ceccato F, Lizzul L, Voltan G, Barbot M, Scaroni C (2021) Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients. Pituitary 24(6):914–921. https://doi.org/10.1007/s11102-021-01165-0
doi: 10.1007/s11102-021-01165-0
pubmed: 34173929
pmcid: 8550050
Finkelstein JS, Whitcomb RW, O’Dea LS, Longcope C, Schoenfeld DA, Crowley WF (1991) Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 73(3):609–620. https://doi.org/10.1210/jcem-73-3-609
doi: 10.1210/jcem-73-3-609
pubmed: 1908484
Ribeiro RS, Abucham J (2009) Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur J Endocrinol 161(1):163–169. https://doi.org/10.1530/EJE-09-0084
doi: 10.1530/EJE-09-0084
pubmed: 19359408
Bell SG, Dalton L, McNeish BL et al (2020) Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients. Gynecol Oncol 159(2):509–514. https://doi.org/10.1016/j.ygyno.2020.08.015
doi: 10.1016/j.ygyno.2020.08.015
pubmed: 32847676
pmcid: 8036903
Rochira V, Kara E, Carani C (2015) The endocrine role of estrogens on human male skeleton. Int J Endocrinol 2015:165215. https://doi.org/10.1155/2015/165215
doi: 10.1155/2015/165215
pubmed: 25873947
pmcid: 4383300
Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet Lond Engl 365(9453):60–62. https://doi.org/10.1016/S0140-6736(04)17666-6
doi: 10.1016/S0140-6736(04)17666-6
Rabaglio M, Sun Z, Price KN et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1–98 trial. Ann Oncol 20(9):1489–1498. https://doi.org/10.1093/annonc/mdp033
doi: 10.1093/annonc/mdp033
pubmed: 19474112
pmcid: 2731016
Gennari L, Nuti R, Bilezikian JP (2004) Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 89(12):5898–5907. https://doi.org/10.1210/jc.2004-1717
doi: 10.1210/jc.2004-1717
pubmed: 15579733
Finkelstein JS, Lee H, Burnett-Bowie SAM et al (2013) Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 369(11):1011–1022. https://doi.org/10.1056/NEJMoa1206168
doi: 10.1056/NEJMoa1206168
pubmed: 24024838
pmcid: 4142768
Carani C, Rochira V, Faustini-Fustini M, Balestrieri A, Granata AR (1999) Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency. Clin Endocrinol (Oxf) 51(4):517–524. https://doi.org/10.1046/j.1365-2265.1999.00849.x
doi: 10.1046/j.1365-2265.1999.00849.x
pubmed: 10583321
Nicoletti I, Filipponi P, Fedeli L, Ambrosi F, Gregorini G, Santeusanio F (1984) Testosterone-induced hyperprolactinaemia in a patient with a disturbance of hypothalamo-pituitary regulation. Acta Endocrinol (Copenh) 105(2):167–172. https://doi.org/10.1530/acta.0.1050167
doi: 10.1530/acta.0.1050167
pubmed: 6695548
Stumpf MAM, Pinheiro FMM, Silva GO et al (2023) How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary 26(2):187–196. https://doi.org/10.1007/s11102-023-01313-8
doi: 10.1007/s11102-023-01313-8
pubmed: 37027090
Heidari Z, Hosseinpanah F, Shirazian N (2010) Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor. Endocr Pract 16(4):669–672. https://doi.org/10.4158/EP10026.CR
doi: 10.4158/EP10026.CR
pubmed: 20439242